D. E. Shaw & Co., Inc. Olema Pharmaceuticals, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OLMA
# of Institutions
136Shares Held
58.7MCall Options Held
141KPut Options Held
23.1K-
Bvf Inc San Francisco, CA9.14MShares$83.8 Million3.47% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.5MShares$50.5 Million2.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$36.7 Million1.76% of portfolio
-
Black Rock Inc. New York, NY4MShares$36.7 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.69MShares$33.8 Million0.12% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $371M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...